Evidence map›Paper›PMID 32831107›Full record

SynthesisSubstance abuse treatment, prevention, and policy2020

Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis.

Salah Eddin Karimi, Azadeh Bayani, Peter Higgs, Amir-Hossein Bayat, Morteza Hemmat, Elahe Ahounbar, Bahram Armoon, Yadolah Fakhri

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Substance abuse treatment, prevention, and policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. The Challenging Road to Hepatitis C Virus Eradication.Journal of clinical medicine · 2021
    Article
  10. Article
  11. Article
  12. Non -fatal overdose among people who inject drugs in Tehran, Iran.Substance abuse treatment, prevention, and policy · 2020
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Salah Eddin KarimiSocial Determinants of Health Research Center, Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Azadeh BayaniStudent Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Peter HiggsDepartment of Public Health, La Trobe University, Melbourne, Australia.
Amir-Hossein BayatSocial Determinants of Health Research Center, Saveh University of Medical Sciences, Saveh, Iran.
Morteza HemmatSocial Determinants of Health Research Center, Saveh University of Medical Sciences, Saveh, Iran.
Elahe AhounbarSubstance Abuse and Dependence Research Center, the University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Bahram ArmoonSocial Determinants of Health Research Center, Saveh University of Medical Sciences, Saveh, Iran. Bahramarmun@gmail.com.ORCID 0000-0001-5467-9889
Yadolah FakhriDepartment of Environmental Health Engineering, Food Health Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Saveh University of Medical Sciences · IRHormozgan University of Medical Sciences · IRLa Trobe University · AUShahid Beheshti University of Medical Sciences · IRTabriz University of Medical Sciences · IRUniversity of Social Welfare and Rehabilitation Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing.

methodsWe searched for studies in English published before May 1, 2020, on PubMed, Scopus, Cochrane, and Web of Science to identify primary studies on the factors associated with hepatitis C virus (HCV) testing among PWID. After reviewing for study duplicates, the full-text of selected articles were assessed for eligibility using Population, Intervention, Comparator, Outcomes (PICO) criteria. i) population: individuals who report injecting drugs; ii) intervention: HCV testing in the past year; iii) comparator: PWIDs who did not have an HCV test; iv) outcome: HCV testing among PWIDs and v) study type: cross-sectional, cohort, and case-control studies. Two independent reviewers (author BA and AB) chose the references in a two-phased monitoring process. The authors gathered data from selected papers, including the surname of the first author, publication date, participant demographic data (age, sex, and level of education) and other characteristics like previous HCV testing, past treatment attempts, duration of injecting drug use and condomless sex. We used fixed and random-effects meta-analysis models to estimate the pooled prevalence, pooled odds ratio (OR), and 95% confidence intervals. The data were analyzed using Stata 12.0 software.

resultsAfter a detailed assessment of over 12,000 articles, a total of 16 studies containing 38,952 participants met the eligibility criteria. Our findings showed a pooled prevalence rate of 61.01% (95% CI, 34.65-84.32%) for recent HCV testing among PWIDs. Being female (OR = 1.69, 95%CI = 1.13, 2.26), aged > 30 years, (OR = 2.61, 95%CI = 1.66-3.56) having past treatment attempt (OR = 2.24, 95%CI = 1.80-2.68), and reporting a previous test (OR = 2.03, 95%CI = 1.23-2.82). were significantly associated with having a recent HCV test.,,. Finding of present study was that unprotected sex had a negative association with HCV testing. Those PWIDs who had unprotected sex were 0.56 times less likely to have completed HCV testing during last year (OR = 0.56, 95%CI = 0.33-0.78).

conclusionPrevention programs that address age > 30 years, being female, past treatment attempt, previous testing of safe sexual practices, are strongly recommended to prioritize HCV risk reduction strategies.

Indexed as

Age FactorsCross-Sectional StudiesDrug UsersGlobal HealthHepatitis CHIV InfectionsHumansPrevalenceRisk-TakingSex FactorsSocial Determinants of HealthSubstance Abuse, IntravenousUnsafe SexPast treatment attemptPrevious testingSocial determinantsUnprotected sex

Identifiers

PMID32831107
PMCPMC7445934
OpenAlexW3081390252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.